These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 32269568)

  • 1. Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
    Leukes V; Walzl G; du Plessis N
    Front Immunol; 2020; 11():451. PubMed ID: 32269568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sildenafil, a Type-5 Phosphodiesterase Inhibitor, Fails to Reverse Myeloid-Derived Suppressor Cell-Mediated T Cell Suppression in Cells Isolated From Tuberculosis Patients.
    Leukes VN; Malherbe ST; Hiemstra A; Kotze LA; Roos K; Keyser A; De Swardt D; Gutschmidt A; Walzl G; du Plessis N
    Front Immunol; 2022; 13():883886. PubMed ID: 35935981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.
    du Plessis N; Kotze LA; Leukes V; Walzl G
    Front Cell Infect Microbiol; 2018; 8():332. PubMed ID: 30298121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis.
    Leukes VN; Dorhoi A; Malherbe ST; Maasdorp E; Khoury J; McAnda S; Walzl G; du Plessis N
    Cell Immunol; 2021 Jun; 364():104359. PubMed ID: 33865151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
    Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
    Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycobacterium tuberculosis and myeloid-derived suppressor cells: Insights into caveolin rich lipid rafts.
    Kotzé LA; Young C; Leukes VN; John V; Fang Z; Walzl G; Lutz MB; du Plessis N
    EBioMedicine; 2020 Mar; 53():102670. PubMed ID: 32113158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Emerging Role of Myeloid-Derived Suppressor Cells in Tuberculosis.
    Magcwebeba T; Dorhoi A; du Plessis N
    Front Immunol; 2019; 10():917. PubMed ID: 31114578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypically resembling myeloid derived suppressor cells are increased in children with HIV and exposed/infected with Mycobacterium tuberculosis.
    Du Plessis N; Jacobs R; Gutschmidt A; Fang Z; van Helden PD; Lutz MB; Hesseling AC; Walzl G
    Eur J Immunol; 2017 Jan; 47(1):107-118. PubMed ID: 27861788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.
    Dorhoi A; Kotzé LA; Berzofsky JA; Sui Y; Gabrilovich DI; Garg A; Hafner R; Khader SA; Schaible UE; Kaufmann SH; Walzl G; Lutz MB; Mahon RN; Ostrand-Rosenberg S; Bishai W; du Plessis N
    J Clin Invest; 2020 Jun; 130(6):2789-2799. PubMed ID: 32420917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates.
    Poitras EL; Gust SL; Kerr PM; Plane F
    Curr Med Chem; 2021; 28(12):2418-2437. PubMed ID: 32964819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment.
    Kim YR; Yang CS
    J Microbiol Biotechnol; 2017 Sep; 27(9):1549-1558. PubMed ID: 28683527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors.
    Jøntvedt Jørgensen M; Jenum S; Tonby K; Mortensen R; Walzl G; Du Plessis N; Dyrhol-Riise AM
    J Leukoc Biol; 2021 Jul; 110(1):177-186. PubMed ID: 33155730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of autophagy mediators in myeloid-derived suppressor cells during human tuberculosis.
    Kotze LA; Leukes VN; Fang Z; Lutz MB; Fitzgerald BL; Belisle J; Loxton AG; Walzl G; du Plessis N
    Cell Immunol; 2021 Nov; 369():104426. PubMed ID: 34469846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.
    Mehta K; Spaink HP; Ottenhoff THM; van der Graaf PH; van Hasselt JGC
    Trends Pharmacol Sci; 2022 Apr; 43(4):293-304. PubMed ID: 34916092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
    Maiga M; Agarwal N; Ammerman NC; Gupta R; Guo H; Maiga MC; Lun S; Bishai WR
    PLoS One; 2012; 7(2):e30749. PubMed ID: 22319585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.
    Maiga M; Ammerman NC; Maiga MC; Tounkara A; Siddiqui S; Polis M; Murphy R; Bishai WR
    J Infect Dis; 2013 Aug; 208(3):512-9. PubMed ID: 23641020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell-killing capability.
    Ribechini E; Eckert I; Beilhack A; Du Plessis N; Walzl G; Schleicher U; Ritter U; Lutz MB
    JCI Insight; 2019 Jun; 5(13):. PubMed ID: 31162143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease.
    Grassi G; Vanini V; De Santis F; Romagnoli A; Aiello A; Casetti R; Cimini E; Bordoni V; Notari S; Cuzzi G; Mosti S; Gualano G; Palmieri F; Fraziano M; Goletti D; Agrati C; Sacchi A
    Front Immunol; 2021; 12():594376. PubMed ID: 33981297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.